Neoadjuvant-Adjuvant Pembrolizumab Therapy Increases Survival in Advanced Skin Cancer

By Oncology Brothers - Last Updated: March 3, 2023

The Oncology Brothers are joined by Dr. Sapna Patel, Director of Unveal Melanoma, Program Director of Melanoma Fellowship, and Associate Professor at the University of Texas – MD Anderson Cancer Center, to discuss melanoma highlights from ESMO 2022. Among the studies discussed, the group detailed a newly published study which showed that pembrolizumab administered both before and after surgery increases event-free survival in patients with resectable stage III/IV melanoma compared with pembrolizumab given after surgery alone.

Advertisement
Advertisement
Latest News

May 30, 2023